Mesothelium pleural cancer, also known as malignant mesothelioma, is a type of cancer that affects the tissue that lines the lungs or abdomen and is usually caused by exposure to asbestos. Asbestos exposure is the main risk factor for mesothelium pleural cancer, and the risk increases with the duration and intensity of the exposure.
As mesothelium pleural cancer is a relatively rare form of cancer, it has not received as much attention as other forms of cancer. However, research into mesothelium pleural cancer is ongoing. Scientists are continuing to work to better understand the causes and treatments of this cancer.
Recent research has focused on the potential of targeted therapies for mesothelium pleural cancer. Targeted therapy is a type of treatment that specifically targets certain molecules or genes associated with cancer cells. This type of therapy is thought to be more effective than traditional treatments such as chemotherapy, radiation therapy, and surgery.
One target of research is the PD-L1 molecule, which is found on the surface of mesothelium pleural cancer cells. It has been found that blocking the PD-L1 molecule can stop the growth of mesothelium pleural cancer cells. Studies have also suggested that targeting the PD-L1 molecule with immunotherapy drugs could be effective in treating mesothelium pleural cancer.
Other targets of research include the VEGF, EGFR, and c-Met pathways, which are involved in the growth and spread of mesothelium pleural cancer cells. Studies have found that blocking these pathways can stop the growth of mesothelium pleural cancer cells.
In addition to targeted therapies, researchers are exploring the potential of immunotherapies for mesothelium pleural cancer. Immunotherapy is a type of treatment that stimulates the body’s own immune system to fight the cancer. Studies have shown that immunotherapy can be effective in treating mesothelium pleural cancer.
Research into mesothelium pleural cancer is ongoing, and scientists are continuing to work to better understand the causes and treatments of this cancer. While there are still many unanswered questions, research is moving in the right direction and new therapies are being developed.